Selected research
Industry Growth & Trends
Global Cystic Fibrosis (CF) Therapeutics Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Cystic Fibrosis (CF) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Cystic Fibrosis (CF) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Cystic Fibrosis (CF) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Cystic Fibrosis (CF) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Cystic Fibrosis (CF) Therapeutics market include Teva Pharmaceutical Industries Ltd, Novartis AG, Merck & Co., Gilead, AbbVie,, AstraZeneca, Vertex Pharmaceuticalsorporated, F. Hoffmann-La Roche Ltd and ALLERGAN, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Cystic Fibrosis (CF) Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Cystic Fibrosis (CF) Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Cystic Fibrosis (CF) Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Cystic Fibrosis (CF) Therapeutics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Cystic Fibrosis (CF) Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Cystic Fibrosis (CF) Therapeutics Market by Company
Teva Pharmaceutical Industries Ltd
Novartis AG
Merck & Co.
Gilead
AbbVie,
AstraZeneca
Vertex Pharmaceuticalsorporated
F. Hoffmann-La Roche Ltd
ALLERGAN
Alcresta
Alaxia
AIT (Advanced Inhalation Therapies)
Cystic Fibrosis (CF) Therapeutics Segment by Type
Bronchodilators
Mucolytics
Pancreatic enzyme supplements
CFTR modulators
Cystic Fibrosis (CF) Therapeutics Segment by Application
Oral drugs
Inhaled drugs
Cystic Fibrosis (CF) Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cystic Fibrosis (CF) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cystic Fibrosis (CF) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cystic Fibrosis (CF) Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Cystic Fibrosis (CF) Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Bronchodilators
- Mucolytics
- Pancreatic enzyme supplements
- CFTR modulators
Applications
- Oral drugs
- Inhaled drugs
Companies covered
- Teva Pharmaceutical Industries Ltd
- Novartis AG
- Merck & Co.
- Gilead
- AbbVie,
- AstraZeneca
- Vertex Pharmaceuticalsorporated
- F. Hoffmann-La Roche Ltd
- ALLERGAN
- Alcresta
- Alaxia
- AIT (Advanced Inhalation Therapies)
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Cystic Fibrosis (CF) Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Cystic Fibrosis (CF) Therapeutics Market Size by Region (2021-2032)
- 1.4.1 Global Cystic Fibrosis (CF) Therapeutics Market Size by Region (2021-2026)
- 1.4.2 Global Cystic Fibrosis (CF) Therapeutics Market Size by Region (2027-2032)
- 1.5 Key Regions Cystic Fibrosis (CF) Therapeutics Market Size (2021-2032)
- 1.5.1 North America Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.4 South America Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate (2021-2032)
2 Cystic Fibrosis (CF) Therapeutics Market by Type
- 2.1 Type Introduction
- 2.1.1 Bronchodilators
- 2.1.2 Mucolytics
- 2.1.3 Pancreatic enzyme supplements
- 2.1.4 CFTR modulators
- 2.2 Global Cystic Fibrosis (CF) Therapeutics Market Size by Type
- 2.2.1 Global Cystic Fibrosis (CF) Therapeutics Market Size Overview by Type (2021-2032)
- 2.2.2 Global Cystic Fibrosis (CF) Therapeutics Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Cystic Fibrosis (CF) Therapeutics Market Size Forecasted by Type (2027-2032)
- 2.3 Global Cystic Fibrosis (CF) Therapeutics Market Size by Regions
- 2.3.1 North America Cystic Fibrosis (CF) Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Cystic Fibrosis (CF) Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Cystic Fibrosis (CF) Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Cystic Fibrosis (CF) Therapeutics Market Size Breakdown by Type (2021-2026)
3 Cystic Fibrosis (CF) Therapeutics Market by Application
- 3.1 Type Introduction
- 3.1.1 Oral drugs
- 3.1.2 Inhaled drugs
- 3.2 Global Cystic Fibrosis (CF) Therapeutics Market Size by Application
- 3.2.1 Global Cystic Fibrosis (CF) Therapeutics Market Size Overview by Application (2021-2032)
- 3.2.2 Global Cystic Fibrosis (CF) Therapeutics Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Cystic Fibrosis (CF) Therapeutics Market Size Forecasted by Application (2027-2032)
- 3.3 Global Cystic Fibrosis (CF) Therapeutics Market Size by Regions
- 3.3.1 North America Cystic Fibrosis (CF) Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Cystic Fibrosis (CF) Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Cystic Fibrosis (CF) Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Cystic Fibrosis (CF) Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Cystic Fibrosis (CF) Therapeutics Industry Trends
- 4.2 Cystic Fibrosis (CF) Therapeutics Industry Drivers
- 4.3 Cystic Fibrosis (CF) Therapeutics Industry Opportunities and Challenges
- 4.4 Cystic Fibrosis (CF) Therapeutics Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Cystic Fibrosis (CF) Therapeutics Revenue (2021-2026)
- 5.2 Global Cystic Fibrosis (CF) Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Cystic Fibrosis (CF) Therapeutics Key Company Headquarters & Area Served
- 5.4 Global Cystic Fibrosis (CF) Therapeutics Company, Product Type & Application
- 5.5 Global Cystic Fibrosis (CF) Therapeutics Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Cystic Fibrosis (CF) Therapeutics Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Cystic Fibrosis (CF) Therapeutics Players Market Share by Revenue in 2025
- 5.6.3 2025 Cystic Fibrosis (CF) Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Teva Pharmaceutical Industries Ltd
- 6.1.1 Teva Pharmaceutical Industries Ltd Company Information
- 6.1.2 Teva Pharmaceutical Industries Ltd Business Overview
- 6.1.3 Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 6.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
- 6.2 Novartis AG
- 6.2.1 Novartis AG Company Information
- 6.2.2 Novartis AG Business Overview
- 6.2.3 Novartis AG Cystic Fibrosis (CF) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Novartis AG Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 6.2.5 Novartis AG Recent Developments
- 6.3 Merck & Co.
- 6.3.1 Merck & Co. Company Information
- 6.3.2 Merck & Co. Business Overview
- 6.3.3 Merck & Co. Cystic Fibrosis (CF) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Merck & Co. Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 6.3.5 Merck & Co. Recent Developments
- 6.4 Gilead
- 6.4.1 Gilead Company Information
- 6.4.2 Gilead Business Overview
- 6.4.3 Gilead Cystic Fibrosis (CF) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Gilead Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 6.4.5 Gilead Recent Developments
- 6.5 AbbVie,
- 6.5.1 AbbVie, Company Information
- 6.5.2 AbbVie, Business Overview
- 6.5.3 AbbVie, Cystic Fibrosis (CF) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 AbbVie, Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 6.5.5 AbbVie, Recent Developments
- 6.6 AstraZeneca
- 6.6.1 AstraZeneca Company Information
- 6.6.2 AstraZeneca Business Overview
- 6.6.3 AstraZeneca Cystic Fibrosis (CF) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 AstraZeneca Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 6.6.5 AstraZeneca Recent Developments
- 6.7 Vertex Pharmaceuticalsorporated
- 6.7.1 Vertex Pharmaceuticalsorporated Company Information
- 6.7.2 Vertex Pharmaceuticalsorporated Business Overview
- 6.7.3 Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 6.7.5 Vertex Pharmaceuticalsorporated Recent Developments
- 6.8 F. Hoffmann-La Roche Ltd
- 6.8.1 F. Hoffmann-La Roche Ltd Company Information
- 6.8.2 F. Hoffmann-La Roche Ltd Business Overview
- 6.8.3 F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 6.8.5 F. Hoffmann-La Roche Ltd Recent Developments
- 6.9 ALLERGAN
- 6.9.1 ALLERGAN Company Information
- 6.9.2 ALLERGAN Business Overview
- 6.9.3 ALLERGAN Cystic Fibrosis (CF) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 ALLERGAN Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 6.9.5 ALLERGAN Recent Developments
- 6.10 Alcresta
- 6.10.1 Alcresta Company Information
- 6.10.2 Alcresta Business Overview
- 6.10.3 Alcresta Cystic Fibrosis (CF) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Alcresta Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 6.10.5 Alcresta Recent Developments
- 6.11 Alaxia
- 6.11.1 Alaxia Company Information
- 6.11.2 Alaxia Business Overview
- 6.11.3 Alaxia Cystic Fibrosis (CF) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Alaxia Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 6.11.5 Alaxia Recent Developments
- 6.12 AIT (Advanced Inhalation Therapies)
- 6.12.1 AIT (Advanced Inhalation Therapies) Company Information
- 6.12.2 AIT (Advanced Inhalation Therapies) Business Overview
- 6.12.3 AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 6.12.5 AIT (Advanced Inhalation Therapies) Recent Developments
7 North America
- 7.1 North America Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2021-2026)
- 7.3 North America Cystic Fibrosis (CF) Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Country (2021-2026)
- 8.3 Europe Cystic Fibrosis (CF) Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2021-2026)
- 10.3 South America Cystic Fibrosis (CF) Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst